Every Form 4 that ResMed Inc. (RMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RMD filings page.
ResMed Chairman and CEO Michael J. Farrell exercised options for 4,991 common shares on October 7, 2026, at an exercise price of $146.34 per share, then sold 4,991 shares at a weighted average price of $226.3349 per share.
The reported transactions were conducted under a Rule 10b5-1 plan adopted October 31, 2024. Following the exercise, the reported option balance was 4,993 options; an indirect holding of 2,090 common shares was reported through the Lisette and Michael Farrell Family Trust.
ResMed Inc. (RMD) amended the ownership report for Michael J. Farrell, Chairman and CEO, to update his reported share position following a previously reported transaction. As of September 8, 2026, the report lists 479,803 shares held directly and 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust.
Justin Leong, ResMed Inc.’s Chief Product Officer, acquired 6,461 shares of ResMed common stock on August 14, 2026, associated with performance-based restricted stock units. The compensation and leadership development committee certified that the applicable performance metrics were met. His reported direct holdings after the transaction were 35,489 shares.
ResMed Inc. reports that Global General Counsel Michael J. Rider acquired 3,230 shares in an award of performance-based restricted stock units earned on August 14, 2026. The units were granted on November 20, 2025, and vest one-third each year on the grant anniversary. Rider’s direct common-stock holdings following the transaction were 12,718 shares.
ResMed Inc. Chairman and CEO Michael J. Farrell reported an award-related acquisition of 13,547 common shares tied to performance-based restricted stock units. The units were granted November 20, 2025, and the shares were earned August 14, 2026, when the compensation committee certified that the performance metrics were met. The units vest one-third each year on the grant anniversary. Farrell's reported direct holdings after the transaction were 479,803 shares; a separate indirect holding lists 2,090 shares in the Lisette and Michael Farrell Family Trust.
ResMed Inc. Chief Financial Officer Aaron Bloomer reported acquiring 9,072 shares of common stock on August 14, 2026, representing performance-based restricted stock units granted June 1, 2026. The units were earned when the compensation and leadership development committee certified that the applicable performance metrics were met. Bloomer reported direct holdings of 9,072 shares following the transaction.
RESMED INC (RMD) reported that Chairman and CEO Michael J. Farrell exercised stock options for 4,991 shares of ResMed common stock on September 8, 2026, at an exercise price of $146.34 per share and sold the same 4,991 shares at a weighted average price of $222.44 per share. The transactions were conducted under a Rule 10b5-1 trading plan adopted October 31, 2024. After the option exercise, Farrell held 9,984 stock options directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.
RESMED INC (RMD) director Peter C. Farrell reported selling 970 shares of ResMed common stock on September 2, 2026 in an open-market or private transaction at $234.73 per share. The sale was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025, and he reported 51,803 shares of direct ownership following the transaction.
ResMed Inc. Chairman and CEO Michael J. Farrell exercised 4,991 options for ResMed Common Stock at an exercise price of $146.34 per share and acquired the same number of shares on August 7, 2026. He then sold 4,991 shares of ResMed Common Stock at a weighted average price of $205.6895 per share, with individual trades ranging from $202.410 to $204.160. The option exercise and related sale were conducted under a Rule 10b5-1 plan adopted October 31, 2024. Following the option transaction, he held 14,975 ResMed Common Stock options and had an indirect holding of 2,090 ResMed Common Stock shares through the Lisette and Michael Farrell Family Trust.
ResMed Inc. director Peter C. Farrell reported selling 8,000 shares of ResMed Common Stock on 2026-08-05 at $225.00 per share in an open-market or private transaction. The sale was conducted under a Rule 10b5-1 plan adopted August 12, 2025.
After this transaction, Farrell directly holds 52,773 shares of ResMed Common Stock.
ResMed Inc Chairman and CEO Michael J. Farrell exercised stock options and sold shares in a pre-planned transaction. He exercised options for 4,991 shares of ResMed common stock at an exercise price of $146.3400 per share, then sold 4,991 shares in open-market trades at a weighted average price of $218.5475 per share.
The sales were executed in multiple trades at prices ranging from $216.772 to $219.700 under a Rule 10b5-1 plan adopted on October 31, 2024. Following the transactions, Farrell directly holds 466,223 shares of ResMed common stock and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust, and 19,966 stock options remain outstanding.
RESMED INC Chairman and CEO Michael J. Farrell reported an exercise-and-sale transaction in company stock. On June 8, 2026, he exercised options to acquire 4,991 shares of ResMed Common Stock at $146.34 per share and sold the same 4,991 shares in open-market trades at a $193.962 weighted average price. The sales were executed in multiple trades between $192.605 and $194.715 under a pre-arranged Rule 10b5-1 plan adopted October 31, 2024. Following these transactions, he directly held 466,256 ResMed shares, with 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust and 24,957 stock options remaining outstanding.
ResMed Inc Global General Counsel Michael J. Rider reported a small tax-related share disposition. On June 1, 2026, 268.742 shares of ResMed common stock were surrendered at $190.57 per share to cover tax withholding on the vesting of Restricted Stock Units that were granted on June 1, 2023. This was a tax-withholding mechanism, not an open-market sale. After this transaction, Rider directly holds 9,488 shares of ResMed common stock, which includes 66.0288 shares purchased on April 30, 2026 through the ResMed Employee Stock Purchase Plan.
ResMed Inc.’s Chairman and CEO Michael J. Farrell reported a same-day option exercise and share sale in ResMed common stock. He exercised options to acquire 4,991 shares at $146.34 per share, then sold 4,991 shares in an open-market transaction at a weighted average price of $207.8206 per share.
After the sale, Farrell directly holds 466,223 ResMed shares and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust. The transactions were conducted on May 7, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2024, indicating a scheduled, routine disposition rather than ad hoc trading.
ResMed Inc.’s Chief Financial Officer Brett Sandercock reported his direct ownership of ResMed Common Stock. Following the reported information, he directly holds 83,495 shares of common stock. The filing reflects his updated ownership position without detailing any specific buy or sell transaction.
ResMed Chairman and CEO Michael J. Farrell exercised stock options and sold the resulting shares in a routine, pre-planned transaction. On April 7, 2026, he exercised options for 4,991 ResMed shares at $146.34 per share, then sold the same 4,991 shares in an open-market sale at a weighted average price of $225.5032.
The sale was conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024, indicating it was pre-scheduled rather than opportunistic. After the transactions, Farrell directly holds 466,223 ResMed shares and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust, so the net shares sold represent a small portion of his overall stake.
RESMED INC Chief Financial Officer Brett Sandercock reported an open-market sale of 1,000 shares of ResMed Common Stock. The shares were sold at a price of $224.31 per share.
After this transaction, he holds 83,495 shares directly. The sale was conducted under a Rule 10b5-1 plan adopted on February 19, 2025.
ResMed Inc. director Peter C. Farrell reported an open-market sale of 2,000 shares of ResMed Common Stock at $225.00 per share. After this transaction, he directly holds 60,773 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than timed discretionarily.
ResMed Inc. Chairman and CEO Michael J. Farrell exercised options to acquire 4,991 shares of ResMed common stock at $146.34 per share, then sold 4,991 shares at a weighted average price of $251.0322 per share. The filing notes the sale was conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he holds 466,223 shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.
ResMed Inc. director Peter C. Farrell sold 2,000 shares of ResMed Common Stock in an open-market transaction. The sale occurred on March 4, 2026 at an average price of $260.22 per share. After this trade, he directly owned 62,773 shares. The transaction was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025.
ResMed Inc.'s Chief Financial Officer Brett Sandercock sold 1,000 shares of ResMed common stock in an open‑market transaction at $254.30 per share on March 2, 2026. The sale was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on February 19, 2025, and he now holds 84,495 shares directly.
ResMed Inc. Chairman and CEO Michael J. Farrell reported an option exercise and related share sale. On February 9, 2026, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, receiving the same number of common shares.
That same day, he sold 4,991 ResMed common shares in market transactions at a weighted average price of $273.7801 per share under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he directly owned 466,223 ResMed common shares and held an additional 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust, along with 44,921 stock options beneficially owned.
ResMed Inc. director Peter C. Farrell, who serves as chairman emeritus, reported selling 2,000 shares of ResMed common stock on February 4, 2026 at a price of $251.31 per share. After this transaction, he beneficially owned 64,773 shares directly. The sale was executed under a pre‑arranged Rule 10b5‑1 trading plan that was adopted on August 12, 2025, indicating the trade followed an advance, systematic plan rather than a discretionary same‑day decision.
ResMed Inc.'s Global General Counsel Michael J. Rider reported a small automatic share sale under a pre-set trading plan. On 02/04/2026, he sold 50 shares of ResMed common stock at $260 per share in a transaction coded as a sale.
After this trade, he beneficially owned 9,691 shares, all reported as directly held. The filing notes that the transaction was conducted under a Rule 10b5-1 plan adopted on February 28, 2025, indicating it was pre-arranged rather than a discretionary market-timed trade.
ResMed Inc.’s Chief Financial Officer Brett Sandercock reported a planned sale of company stock. On February 2, 2026, he sold 1,000 shares of ResMed common stock at $257.03 per share under a Rule 10b5-1 trading plan adopted on February 19, 2025.
After this transaction, Sandercock directly holds 85,495 ResMed shares. Rule 10b5-1 plans allow executives to pre-schedule trades, helping separate routine portfolio moves from day-to-day market or company news.
ResMed Inc. director Peter C. Farrell reported a sale of company stock. On January 7, 2026, he sold 2,000 shares of ResMed common stock at a price of $248.83 per share. After this transaction, he beneficially owned 66,773 shares directly. The filing notes that the trade was conducted under a Rule 10b5-1 trading plan that was adopted on August 12, 2025, which is a pre-arranged plan that allows insiders to systematically sell shares over time.
ResMed Inc.'s Chairman and CEO Michael J. Farrell reported an options exercise and stock sale. On January 7, 2026, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, receiving the same number of ResMed common shares. On the same day, he sold 4,991 ResMed common shares at a weighted average price of $248.4603 per share, in multiple trades between $246.801 and $249.969.
The transactions were conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. Following these transactions, Farrell directly beneficially owned 466,223 ResMed common shares, held in his own name, and indirectly beneficially owned 2,090 shares through the Lisette and Michael Farrell Family Trust. He also held 49,912 ResMed common stock options after the reported exercise; these options first became exercisable on November 11, 2020 and vest one-third per year.
ResMed Inc.'s Chief Financial Officer reported a small planned share sale. On 01/02/2026, the CFO sold 1,000 shares of ResMed common stock at a price of $241.75 per share in an open market transaction coded as a sale. The filing shows that after this transaction, the officer directly beneficially owns 86,495 shares of ResMed common stock.
The transaction was made under a Rule 10b5-1 trading plan that was adopted on February 19, 2025, indicating it was pre-arranged under SEC rules rather than a discretionary trade at the time of sale.
ResMed Inc.'s Global General Counsel and Secretary reported a small stock sale in a Form 4 filing. On 01/02/2026, the officer sold 50 shares of ResMed common stock at a price of $241.75 per share. After this transaction, the officer beneficially owned 9,741 shares, held directly.
The filing notes that this transaction was conducted under a pre-established Rule 10b5-1 trading plan that was adopted on February 28, 2025. Such plans allow insiders to sell shares according to predetermined instructions, helping separate routine portfolio management from the timing of any company news.
ResMed Inc. Chairman and CEO Michael J. Farrell reported an option exercise and share sale. On 12/08/2025, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, converting them into the same number of common shares.
On the same date, he sold 4,991 ResMed common shares at a weighted average price of $251.4117 per share under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he directly owned 466,223 ResMed shares, held 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust, and beneficially owned 54,903 stock options with underlying ResMed shares.
ResMed Inc. director reports planned stock sale. A reporting person serving as a director of ResMed Inc. (ticker RMD) sold 2,000 shares of ResMed common stock on 12/03/2025 at a price of $251.47 per share. The transaction was coded as a sale and was made under a Rule 10b5-1 trading plan adopted on August 12, 2025, which allows pre-arranged trades according to preset instructions. Following this sale, the insider directly beneficially owns 68,773 shares of ResMed common stock, reflecting the remaining stake reported in this filing.
ResMed Inc. reported an insider stock sale by its Global General Counsel. The Form 4 shows that officer Michael J. Rider sold 50 shares of ResMed common stock on 12/01/2025 at a price of $244.16 per share. After this transaction, he beneficially owned 9,791 shares of ResMed common stock directly.
The filing notes that the sale was made under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 28, 2025, which is designed to allow insiders to sell shares according to a set schedule.
ResMed Inc.'s Chief Financial Officer reports a routine stock sale. On 12/01/2025, the CFO sold 1,000 shares of ResMed common stock at a price of $244.16 per share in an open market transaction. The filing notes that this sale was conducted under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 19, 2025, which is designed to allow insider transactions under preset instructions.
After this transaction, the CFO continues to beneficially own 87,495 ResMed shares, held directly. The filing does not report any derivative securities transactions, indicating that this update relates only to common stock ownership.
ResMed Inc. (RMD) reported an equity compensation grant to its Chairman and CEO on a Form 4. On 11/24/2025, he received options to purchase 33,288 shares of ResMed common stock at an exercise price of $250.52 per share. These options first become exercisable on 11/11/2026 and vest in three equal annual installments starting on that date, aligning his incentives with longer-term company performance. Following this grant, he beneficially owns 466,223 shares of ResMed common stock held directly.
ResMed Inc. (RMD) reported that one of its directors received a grant of 1,331 stock options on ResMed common stock with an exercise price of $250.52 per share. These options become exercisable on the earlier of November 11, 2026, or the date of the first annual meeting of stockholders following the grant date, and expire on November 11, 2032.
After this reported transaction, the director beneficially owns 70,773 shares of ResMed common stock directly, as well as 1,331 stock options directly.
ResMed Inc. (RMD) director files Form 4 for planned stock sale. Director Jan De Witte reported selling 2,055 shares of ResMed common stock on 11/25/2025 at a price of $255 per share. After this transaction, De Witte beneficially owns 4,261 shares, held directly.
The sale was coded as an "S" transaction and was carried out under a Rule 10b5-1 trading plan adopted on August 18, 2025, indicating it was pre-arranged under preset instructions rather than a discretionary, one-off trade.
ResMed Inc. director Nicole Mowad-Nassar reported equity transactions involving the company’s stock. As a member of the board of directors, she filed a Form 4 as a single reporting person.
On 11/24/2025, she was granted stock options on 1,331 shares of ResMed common stock at an exercise price of $250.52 per share. These options become exercisable on the earlier of November 11, 2026, or the date of the first annual meeting of stockholders following the grant date. The filing also shows a disposition of 777 shares of ResMed common stock, reflecting routine personal trading activity by a director.
ResMed Inc. (RMD) filed a Form 4 disclosing that its Chief Product Officer acquired 1,848 shares of common stock on 11/20/2025. These shares came from performance-based restricted stock units that were originally granted on November 16, 2022 and were earned when the compensation and leadership development committee certified that the performance targets were met.
After this transaction, the officer beneficially owns 29,028 shares of ResMed common stock in direct ownership. The transaction was reported as an acquisition at a price of $0, reflecting the vesting of equity compensation rather than an open-market purchase.
ResMed Inc. (RMD) reported a director equity grant on a Form 4. On 11/20/2025, a company director acquired 1,073 shares of ResMed common stock through a stock award at a stated price of $0 per share, reflecting a grant of restricted stock units.
After this transaction, the reporting person beneficially owned 5,118 shares of ResMed common stock in direct ownership. The restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning the director’s compensation with shareholder interests over that period.
ResMed Inc. (RMD) reported an insider equity award for director Nicole Mowad-Nassar on a Form 4. On 11/20/2025, she received 536 shares of ResMed common stock as a grant of restricted stock units at a stated price of $0 per share, reflecting a stock-based award rather than an open-market purchase. Following this transaction, she beneficially owned 777 shares directly.
The filing notes that these restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders held in the year following the grant date. This is a routine director compensation transaction and does not involve any derivative securities.
ResMed Inc. director Desney Tan reported receiving a new equity award from the company. On 11/20/2025, he acquired 1,073 shares of ResMed common stock through a grant priced at $0, increasing his directly owned stake to 6,002 shares after the transaction.
The award is in the form of restricted stock units (RSUs), which are shares that Tan will receive once they vest. These RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, meaning the shares are subject to a service-based vesting condition tied to time and board tenure.
ResMed Inc. (RMD) reported that director Harjit Gill received an equity award in the form of 1,073 restricted stock units (RSUs) of ResMed common stock on 11/20/2025. The RSUs were granted at a price of $0 per unit, reflecting a typical director equity grant rather than an open‑market purchase.
After this award, Gill beneficially owns 10,940 shares of ResMed common stock. The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, tying the equity award to continued board service over roughly a one‑year cycle.
ResMed Inc. (RMD) reported an equity grant to director Karen Drexler. On 11/20/2025, she acquired 1,073 shares of ResMed common stock through a grant of restricted stock units at a stated price of $0 per share.
The restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date. After this award, Karen Drexler beneficially owned 10,602 shares directly.
ResMed Inc. (RMD) director Carol Burt reported a grant of 1,073 shares of ResMed common stock in the form of restricted stock units. These RSUs were awarded on 11/20/2025 at a price of $0 per share, reflecting a typical equity compensation grant for a board member rather than an open-market purchase.
Following this award, she reported 2,156 shares of ResMed common stock held directly and an additional 16,660 shares held indirectly through the Carol Burt Hilliard Trust. The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, tying the equity award to her continued board service.
ResMed Inc. (RMD) reported a change in director ownership through a Form 4 filing. Director Ronald Taylor received an award of 1,073 shares of ResMed common stock on 11/20/2025 at a stated price of $0, reflecting a grant rather than an open-market purchase. Following this transaction, he beneficially owns 24,771 shares directly.
The shares awarded are in the form of Restricted Stock Units (RSUs). These RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning the director’s compensation with the company’s long-term performance and shareholder interests.
ResMed Inc. (RMD) Chief Financial Officer Brett Sandercock reported an equity award vesting. On 11/20/2025, he acquired 2,710 shares of ResMed common stock at a price of $0 per share, reflecting the earning of performance-based restricted stock units originally granted on 11/16/2022. The compensation and leadership development committee certified that the required performance metrics were met, which triggered the share delivery.
Following this transaction, Sandercock beneficially owns 88,495 shares of ResMed common stock in direct ownership. This filing is a routine disclosure of insider equity compensation vesting and does not indicate an open-market purchase or sale.
ResMed Inc. (RMD) Chairman and CEO Michael J. Farrell reported routine equity compensation activity. On 11/20/2025, he acquired 13,551 shares of ResMed common stock at $0, following the earning of performance-based restricted stock units that were granted on November 16, 2022 and certified as earned by the compensation and leadership development committee.
On the same date, 7,297 shares were disposed of at $0 to ResMed to cover tax withholding on the vesting. After these transactions, Farrell beneficially owned 466,223 shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.
ResMed Inc. (RMD) reported an insider equity award for director Christopher DelOrefice. On 11/20/2025, he acquired 1,073 shares of ResMed common stock at a price of $0, reported as an award of restricted stock units. After this transaction, he beneficially owns 2,423 shares directly.
The filing notes that these restricted stock units (RSUs) vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, tying the award to continued board service.
ResMed Inc. director equity grant reported on Form 4. Director Jan De Witte reported receiving 1,073 shares of ResMed common stock in the form of restricted stock units on 11/20/2025 at a price of $0 per share. After this grant, De Witte beneficially owns 6,316 shares directly. The restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning director compensation with the company’s long‑term performance.
ResMed Inc. (RMD) director Peter C. Farrell reported an equity award under a director compensation program. On 11/20/2025, he acquired 536 shares of ResMed common stock at a stated price of $0, reported as an acquisition of non-derivative securities. Following this transaction, he beneficially owned 70,773 shares held directly.
The filing explains that these shares were awarded in the form of Restricted Stock Units (RSUs). The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning the director’s compensation with shareholder interests over that period.